Dr. Shain on Subcutaneous Therapy for Patients With Multiple Myeloma

Kenneth H. Shain, MD, PhD
Published: Tuesday, Aug 08, 2017



Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses the impact of subcutaneous therapy, such as bortezomib (Velcade) and daratumumab (Darzalex) for patients with multiple myeloma.

For certain drugs, subcutaneous use of therapy will be important for the field of myeloma, Shain explains. It has changed how physicians take care of patients in helping to mitigate some toxicities, as seen with subcutaneous treatment with bortezomib.

The implementation of this is something that’s going to take time, he says, as it is more of a delivery change versus a mitigation of toxicity change.


Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses the impact of subcutaneous therapy, such as bortezomib (Velcade) and daratumumab (Darzalex) for patients with multiple myeloma.

For certain drugs, subcutaneous use of therapy will be important for the field of myeloma, Shain explains. It has changed how physicians take care of patients in helping to mitigate some toxicities, as seen with subcutaneous treatment with bortezomib.

The implementation of this is something that’s going to take time, he says, as it is more of a delivery change versus a mitigation of toxicity change.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x